Prolia

Type: Product
Name: Prolia
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Amgen to cut up to 3,000 jobs, most in U.S., close facilities

Amgen has announced a restructuring plan to invest in continuing innovation and the launch of its new pipeline molecules, while improving cost structure.Initial efforts include streamlining the organization, reducing layers of management, increasing managerial ... [Published Center Watch - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Amgen reports bumper results... then wields job axe new

Amgen is the world's biggest maker of biologic drugs– 31 July 2014Biologic drug-maker Amgen is to shed 12% to 15% of its worldwide workforce and close four sites, despite reporting stellar second-quarter results that trounced Wall Street expectations ... [Published Belfast Telegraph - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 3 reports

Amgen Q2 sales rise, company to lay off up to 2,900

Share this article:Prolia sales soar 40%, to $264 million, compared to the same period last yearAmgen powered through its second quarter with sales rising to $4.9 billion, up 8% compared to the same period last year, when sales hit $4.6 billion.Much of ... [Published Medical Marketing And Media - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 4 reports

Amgen Pleases the Street -- but Will Layoffs Keep Critics at Bay?

NEW YORK (TheStreet) -- Amgen,  the sprawling biotechnology company, pleased investors with higher profits and big layoffs yesterday, but its moves will not quiet those who want a more basic restructuring.The maker of the osteoporosis drug Prolia said ... [Published West Hartford News - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Amgen Price Target Raised by Various Analysts

Analysts were upbeat following Amgen's (NASDAQ: AMGN) solid second quarter results after the company reported after the bell on Tuesday.Credit Suisse raised its price target and earnings target for Amgen. This came as a result of Amgen offering a higher ... [Published Benzinga.com - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Amgen Reports Stellar Earnings, Raises Guidance

Amgen (NASDAQ: AMGN ) moved higher after-hours Tuesday following a mixed quarterly earnings report, but stellar guidance.Amgen reported GAAP EPS growth of 22 percent, EPS grew from $1.65 in Q2 2013 to $2.01 in Q2 2014. Consensus EPS estimates (adjusted) ... [Published Yahoo! Finance - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Amgen to Lay off up to 2,900; 2Q Revenues up 11 Percent

Amgen reported that its total revenues increased 11 percent to $5,180 million, with 8 percent product sales growth driven by strong performance across the portfolio, particularly Enbrel (etanercept), Kyprolis (carfilzomib), Prolia (denosumab) and XGEVA ... [Published Pharmaceutical Manufacturing Magazine - Jul 30 2014]
Entities: Amgen Inc, Enbrel, Denosumab
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

ACCURACY, FAST RESPONSE AND CONVENIENCE GOAL OF BBGH INFUSION DEPARTMENT

Posted 1 hour agoBy Kevin HornInfusion Department Coordinator Jenni Johnson, RN, BSN, pauses for a moment after starting a Venofer infusion for a patient needing the outpatient procedure. As can be seen, IV’s used in the department are no different than ... [Published Panhandle Post - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Dr. Keith Roach: Patient prefers to split thyroid meds

Dear Dr. Roach: I had my thyroid removed for a goiter 35 years ago. My doctor put me on 100 mcg of thyroid medication; however, when I took it, I got sick. My hands shook, and my heart beat very quickly (over 100). So one doctor told me to split it, and ... [Published Herald & Review - Jul 28 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 2 reports

GlaxoSmithKline slashes forecast as 2nd-qtr sales and earnings fall sharply

UK pharma giant GlaxoSmithKline (LSE: GSK) saw its shares fall 3.9% to £45.94 shortly after the company reported disappointing second-quarter 2014 financial results, and chief executive Sir Andrew Witty admitted that "it is now unlikely that we will deliver ... [Published Pharma Letter - Jul 24 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Human medicines European public assessment report (EPAR): Prolia, denosumab, Revision: 5, Authorised

Entities: Prolia, Denosumab
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Global Osteoporosis Market & Drugs Analysis

Dallas, TX -- ( SBWIRE ) -- 07/02/2014 -- Osteoporosis is often called the "silent disease" because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility ... [Published SBWire - Jul 02 2014]
Entities: Osteoporosis, Prolia, Drugs

Quotes

...have been very supportive, so it is with great reluctance that we acknowledge the need to exit," said Robert A Bradway, Amgen’s chairman and CEO. "At each site, we are actively engaging in discussions with third parties about potential future use of the facilities."
Research head, Sean Harper, said: "We have an unprecedented number of late-stage programmes rolling through at the moment."
Poydras' reaction to the layoff news was to call it "less of a restructuring and more of a re-allocation! Unlikely that this will appease dissatisfied investors who are looking for real savings, not just moving things around." Poydras in the past has suggested that Amgen split itself into two companies, one focused on exploiting existing drugs for dividends and the other focused...
...growth through the first half of 2014 affirms the underlying strength of our business," said Robert Bradway, chairman and chief executive, adding: "We are making excellent progress in advancing our pipeline as we prepare to launch a number of promising new innovative medicines. From a position of strength, we have announced today restructuring initiatives that will allow us to reallocate resources to invest in our upcoming launches and drive growth."

More Content

All (34) | News (32) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Amgen to cut up to 3,000 jobs, most in U.S., cl... [Published Center Watch - Jul 31 2014]
Amgen reports bumper results... then wields job... [Published Belfast Telegraph - Jul 31 2014]
Amgen Q2 sales rise, company to lay off up to 2... [Published Medical Marketing And Media - Jul 31 2014]
Amgen - Continued Appeal With Shares Trading At... [Published Seeking Alpha - Jul 30 2014]
Amgen Price Target Raised by Various Analysts [Published Benzinga.com - Jul 30 2014]
Amgen, Inc. (AMGN) Announces Revenue Growth And... [Published InsiderMonkey.com - Jul 30 2014]
Amgen Pleases the Street -- but Will Layoffs Ke... [Published West Hartford News - Jul 30 2014]
Amgen Reports Stellar Earnings, Raises Guidance [Published Yahoo! Finance - Jul 30 2014]
Amgen’s 2nd-qtr beats expectations, but firm sl... [Published Pharma Letter - Jul 30 2014]
Amgen to wield axe on 2,900 jobs [Published Pharmafocus - Jul 30 2014]
Amgen to Lay off up to 2,900; 2Q Revenues up 11... [Published Pharmaceutical Manufacturing Magazine - Jul 30 2014]
Amgen (AMGN) CEO Bob Bradway on Q2 2014 Results... [Published Seeking Alpha - Jul 30 2014]
Biotech giant axes up to 2,900 jobs [Published BT.com - Jul 30 2014]
Biotech drugmaker Amgen laying off at least 2,400 [Published Kentucky.com - Jul 30 2014]
ACCURACY, FAST RESPONSE AND CONVENIENCE GOAL OF... [Published Panhandle Post - Jul 30 2014]
Will Amgen (AMGN) Disappoint This Earnings Season? [Published Zacks.com - Jul 28 2014]
Dr. Keith Roach: Patient prefers to split thyro... [Published Herald & Review - Jul 28 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Jul 25 2014]
GlaxoSmithKline slashes forecast as 2nd-qtr sal... [Published Pharma Letter - Jul 24 2014]
Ultragenyx Appoints Sunil Agarwal, M.D. as Chie... [Published EMoneyDaily - Jul 23 2014]
Half Yearly Report [Published TrustNet - Jul 23 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 11 2014]
A Real Dividend Growth Machine: Q2 2014 Review [Published Seeking Alpha - Jul 08 2014]
Citi Sees Plenty Of Q2 Earnings Beats Ahead In ... [Published Benzinga.com - Jul 03 2014]
Global Osteoporosis Market & Drugs Analysis [Published SBWire - Jul 02 2014]
Winners of the inaugural Creative Floor Awards ... [Published Pharma Times - Jul 02 2014]
1st Quarter Results [Published TrustNet - Apr 30 2014]
Amgen's net earnings dips by 25% to $1,073 mill... [Published PharmaBiz - Apr 23 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
Top 15 global pharma cos report disappointing r... [Published PharmaBiz - Mar 10 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 11 2014]
Prolia - Insurance [Published HealthBoards - Feb 15 2014]
My husband and I are moving to the Tampa Bay, FL, area and I am insurance shopping. So far Humana has a couple plans that could work. Does anyone have experience with Humana paying for or not paying for Prolia injections? ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.